Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tempol - DMK Pharmaceuticals /Matrix Biomed

Next Previous
X
Search
Drug Profile

Tempol - DMK Pharmaceuticals /Matrix Biomed

Alternative Names: APC-400; APC-410; MBM 02; MBM-01; MTS-01; MTS-02; MTS-10

Latest Information Update: 13 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Matrix Biomed
  • Developer DMK Pharmaceuticals; Matrix Biomed
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antineoplastics; Antivirals; Cytoprotectives; Eye disorder therapies; Piperidines; Radioprotectives; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Blood coagulation factor inhibitors; Inflammation mediator inhibitors; RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Radiodermatitis
  • Phase II/III COVID 2019 infections
  • Phase II Chemotherapy-induced damage; Glioblastoma; Neuropathic pain; Prostate cancer
  • No development reported Glaucoma

Most Recent Events

  • 07 Sep 2023 Adamis Pharmaceuticals Corporation is now called DMK Pharmaceuticals
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Glaucoma(Prevention) in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top